CO5570687A2 - VALDECOXIB INTRAORAL DISGREGATION COMPOSITIONS PREPARED BY A SPRAY DESECTION PROCEDURE - Google Patents

VALDECOXIB INTRAORAL DISGREGATION COMPOSITIONS PREPARED BY A SPRAY DESECTION PROCEDURE

Info

Publication number
CO5570687A2
CO5570687A2 CO04033066A CO04033066A CO5570687A2 CO 5570687 A2 CO5570687 A2 CO 5570687A2 CO 04033066 A CO04033066 A CO 04033066A CO 04033066 A CO04033066 A CO 04033066A CO 5570687 A2 CO5570687 A2 CO 5570687A2
Authority
CO
Colombia
Prior art keywords
valdecoxib
composition
pharmaceutically acceptable
oral dissolution
desection
Prior art date
Application number
CO04033066A
Other languages
Spanish (es)
Inventor
Joseph P Reo
J Shah Uday
Yamamoto Ken
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5570687A2 publication Critical patent/CO5570687A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)

Abstract

1.- Una composición oral de disolución rápida que comprende:(a) un particulado de valdecoxib en una cantidad terapéuticamente efectiva, y (b) al menos un excipiente farmacéuticamente aceptable que muestra una rápida disolución oral y que está en asociación íntima con las partículas de valdecoxib;en la que el al menos un excipiente que muestra una rápida disolución oral está presente en una cantidad total de aproximadamente el 50% a aproximadamente el 99% en peso.2.- La composición de la Reivindicación 1, en la que el al menos un excipiente farmacéuticamente aceptable que muestra una rápida disolución oral es un carbohidrato.3.- La composición de la Reivindicación 1, en la que el al menos un excipiente farmacéuticamente aceptable que muestra una rápida disolución oral es un sacárido.4.- La composición de la Reivindicación 1, en la que el al menos un excipiente farmacéuticamente aceptable que muestra una rápida disolución oral se elige del grupo consistente en maltosa, maltitol, sorbitol, lactosa y manitol.5.- La composición de la Reivindicación 1, en la que el al menos un excipiente que muestra una rápida disolución oral esta presente en una cantidad total de aproximadamente el 50% a aproximadamente el 90% en peso.1. An oral fast-dissolving composition comprising: (a) a particulate of valdecoxib in a therapeutically effective amount, and (b) at least one pharmaceutically acceptable excipient that shows rapid oral dissolution and is in intimate association with the particles of valdecoxib, wherein the at least one excipient showing rapid oral dissolution is present in a total amount of about 50% to about 99% by weight. 2. The composition of Claim 1, wherein the At least one pharmaceutically acceptable excipient showing rapid oral dissolution is a carbohydrate. 3. The composition of Claim 1, wherein the at least one pharmaceutically acceptable excipient showing rapid oral dissolution is a saccharide. Composition of Claim 1, wherein the at least one pharmaceutically acceptable excipient showing rapid oral dissolution is selected from the group consisting of in maltose, maltitol, sorbitol, lactose and mannitol. 5. The composition of Claim 1, wherein the at least one excipient showing rapid oral dissolution is present in a total amount of about 50% to about 90 % in weigh.

CO04033066A 2001-10-10 2004-04-07 VALDECOXIB INTRAORAL DISGREGATION COMPOSITIONS PREPARED BY A SPRAY DESECTION PROCEDURE CO5570687A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32808801P 2001-10-10 2001-10-10

Publications (1)

Publication Number Publication Date
CO5570687A2 true CO5570687A2 (en) 2005-10-31

Family

ID=23279455

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04033066A CO5570687A2 (en) 2001-10-10 2004-04-07 VALDECOXIB INTRAORAL DISGREGATION COMPOSITIONS PREPARED BY A SPRAY DESECTION PROCEDURE

Country Status (28)

Country Link
EP (1) EP1450769A1 (en)
JP (1) JP2005508348A (en)
KR (1) KR20050035138A (en)
CN (1) CN1602187A (en)
AP (1) AP2004003022A0 (en)
BG (1) BG108675A (en)
BR (1) BR0213152A (en)
CA (1) CA2462881A1 (en)
CO (1) CO5570687A2 (en)
CZ (1) CZ2004456A3 (en)
EA (1) EA200400423A1 (en)
EC (1) ECSP045056A (en)
GE (1) GEP20063857B (en)
HR (1) HRP20040331A2 (en)
HU (1) HUP0401776A2 (en)
IL (1) IL161253A0 (en)
IS (1) IS7211A (en)
MA (1) MA27543A1 (en)
MX (1) MXPA04003404A (en)
NO (1) NO20041894L (en)
NZ (1) NZ532184A (en)
OA (1) OA12666A (en)
PL (1) PL370136A1 (en)
SK (1) SK1662004A3 (en)
TN (1) TNSN04056A1 (en)
WO (1) WO2003030876A1 (en)
YU (1) YU37104A (en)
ZA (1) ZA200402728B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
WO2012087113A1 (en) * 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
KR100373622B1 (en) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 One-time therapeutic composition for diseases mediated with cyclooxygenase-2
KR100664479B1 (en) * 1999-12-08 2007-01-04 파마시아 코포레이션 Valdecoxib composition
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020071857A1 (en) * 2000-08-18 2002-06-13 Kararli Tugrul T. Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
CN1638739A (en) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 Compound for treating assuetude disturbance

Also Published As

Publication number Publication date
IL161253A0 (en) 2004-09-27
CZ2004456A3 (en) 2005-03-16
HRP20040331A2 (en) 2005-12-31
CA2462881A1 (en) 2003-04-17
NO20041894D0 (en) 2004-05-07
GEP20063857B (en) 2006-06-26
YU37104A (en) 2006-08-17
NZ532184A (en) 2005-12-23
WO2003030876A1 (en) 2003-04-17
CN1602187A (en) 2005-03-30
BR0213152A (en) 2004-10-19
PL370136A1 (en) 2005-05-16
AP2004003022A0 (en) 2004-06-30
HUP0401776A2 (en) 2004-12-28
BG108675A (en) 2005-03-31
EP1450769A1 (en) 2004-09-01
ECSP045056A (en) 2004-08-27
JP2005508348A (en) 2005-03-31
TNSN04056A1 (en) 2006-06-01
MXPA04003404A (en) 2004-06-18
MA27543A1 (en) 2005-10-03
IS7211A (en) 2004-04-07
OA12666A (en) 2006-06-19
KR20050035138A (en) 2005-04-15
SK1662004A3 (en) 2005-07-01
EA200400423A1 (en) 2004-10-28
ZA200402728B (en) 2005-03-17
NO20041894L (en) 2004-07-07

Similar Documents

Publication Publication Date Title
CO5570684A2 (en) ORGANOLEPTICALLY ACCEPTABLE INTRAORAL DISGREGATION COMPOSITIONS
AR020015A1 (en) CELECOXIB COMPOSITIONS
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
CO5251419A1 (en) NANOPARTICULATED COMPOSITIONS OF EPLERENONA
ME00347B (en) Pramipexole once-daily dosage form
HRP20220902T3 (en) Compositions and uses for treating multiple sclerosis
AR035927A1 (en) LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
PE20040121A1 (en) CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF 5,8,14-TRIAZATETRACICLO [10.3.1.02,11.04.9] -HEXADECA-2- (11), 3,5,7,9-PENTAENE
KR970706814A (en) Freeze-Dried Ondansetron Compositions
HRP20161082T1 (en) Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent
BR9909915A (en) Adjuvant compositions
ATE264102T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE WITH RAPID TRANSMUCOSAL ABSORPTION
AR019935A1 (en) SOLID PREPARATION OF QUICK DISINTEGRATION, USE OF A LITTLE CELLULOSE HYDROXIPROPIL REPLACED IN SUCH PREPARATION AND METHOD TO IMPROVE THE CAPACITY OF FAST DETACHMENT OF THE SAME
ECSP066807A (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
CO5390076A1 (en) PHARMACEUTICAL COMPOSITIONS
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
CO5280073A1 (en) COMPOSITIONS
AR062659A1 (en) COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE
JP2005520779A5 (en)
AR008977A1 (en) ORIGINALLY ADMINISTRABLE SOLID DOSAGE FORMS OF RIBAVIRIN, RIBAVIRIN COMPOSITION AND METHOD FOR PRODUCING SUCH COMPOSITION
AP2003002763A0 (en) Controlled release formulations for oral administration
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
HUP0402178A2 (en) Pharmaceutical composition comprising a 5 hti receptor agonist
PL1778209T3 (en) Methods and compositions for oral delivery of fts

Legal Events

Date Code Title Description
FC Application refused